(Feb. 15, 2022) BarkerGilmore, a boutique firm specializing in legal and compliance executive search and leadership development, congratulates Senior Advisor, Marla Persky, on her newest leadership role as a member of the board of directors (Chair, Nomination and Governance Committee) at clinical-stage pharmaceutical company, Panavance Therapeutics Inc.
“Panavance’s leadership team is tirelessly committed to developing therapies that will improve the outcomes and lives of cancer patients,” said Marla. “The company’s clinical stage asset, GP-2250, has the potential to make a meaningful impact across diverse oncological disease states and therapeutic applications by targeting the primary source of cancer cell energy production with its unique and patent-pending mechanism of action – and I am both honored and excited to join that effort in this way.”
Marla brings more than 20 years of experience leading global pharmaceutical, medical device, diagnostic, biologic, and OTC product businesses and legal departments. She is the former Senior Vice President, General Counsel, and Corporate Secretary for Boehringer Ingelheim USA, the largest privately-owned pharmaceutical company in the world, where she oversaw a 70-member department. She was also a member of Boehringer’s executive management team and a director of the company and several of its subsidiaries. Before joining Boehringer Ingelheim, Marla spent 19 years at Baxter International Inc., where she held numerous business and legal positions, most recently Global General Counsel and Corporate Secretary.
“To achieve its stated mission of ‘disrupting cancer’s energy,’ Panavance will continue to rely upon its Board of Directors to help Management set strategic direction – and they have found just this kind of insightful and indefatigable resource in Marla,” said BarkerGilmore Managing Partner, Bob Barker. “Our own clients, whom Marla has assisted in her capacity as a Senior Advisor, would no doubt readily agree.”
Marla also currently serves on the Audit and Strategic Planning Committees of the board of directors of medical technology company, YGEIA; as a member of the Audit Committee and Chair, Nominating/Governance Committee for Xeris Pharmaceuticals, Inc.; and as a member of the board of directors of REVOLO Biotherapeutics. She is a also involved with non-profit organizations as Chair of the Investment Committee, and a member of the Audit Committee for World Neighbors; Director and President of the board for Primary Stages; and Director, Chair of the Audit Committee, and a member of the Governance and Patient Access Committees for The Leukemia & Lymphoma Society. Marla was previously on the boards of Watermark Publishing, Inc., Cytyc Corporation, and Boehringer Ingelheim Corporation.
A frequent speaker on leadership principles, mentoring, diversity, crisis management, and negotiation techniques, Marla additionally serves as CEO and President of WOMN LLC, an organization dedicated to increasing diversity in the legal profession and helping women and minority attorneys succeed in the business of law.
Panavance Therapeutics Inc. is a clinical-stage pharmaceutical company established in 2021 by Avensis Pharma AG, a subsidiary of Ed. Geistlich Söhne AG für Chemische Industrie, in order to advance the development of GP-2250, a novel oncology therapeutic intended to improve the effectiveness of cancer treatments and quality of life for the patients that receive them. With its highly capable team and strong academic and industry partnerships, Panavance is pursuing a rigorous program to bring GP-2250 to patients around the world. To date, their therapeutic has demonstrated substantial efficacy and safety in extensive preclinical studies, and its early clinical results have been encouraging. Panavance has developed a clear pathway to US registration of GP-2250 for pancreatic cancer.
BarkerGilmore is a boutique firm recognized by CEOs, boards, and executives as best-in-class legal and compliance executive search professionals and leadership consultants. With a team of advisors and recruiters spanning the United States, BarkerGilmore’s client roster includes leading consumer, energy, financial, healthcare & life science, industrial, non-profit, private equity, and technology companies. In addition, as a prominent thought leader within the legal industry, BarkerGilmore has released various reports to inform the conversations on in-house counsel compensation, the crucial role of the General Counsel as both a legal advisor and business partner, and General Counsel succession planning. For further information visit barkergilmore.com or call 877-571-5047.